vs
PJT Partners Inc.（PJT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是PJT Partners Inc.的1.2倍（$622.0M vs $531.4M），Royalty Pharma plc净利率更高（34.4% vs 10.0%，领先24.4%），PJT Partners Inc.同比增速更快（12.9% vs 4.8%），过去两年PJT Partners Inc.的营收复合增速更高（27.5% vs 4.6%）
PJT Partners Inc.是一家专注于顾问业务的全球投资银行，于2015年10月从黑石集团旗下拆分成立，独立运营原黑石的金融与战略咨询服务业务，为全球各类客户提供专业的投行顾问相关服务。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
PJT vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.2倍
$531.4M
营收增速更快
PJT
高出8.2%
4.8%
净利率更高
RPRX
高出24.4%
10.0%
两年增速更快
PJT
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $531.4M | $622.0M |
| 净利润 | $53.4M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 23.1% | 62.4% |
| 净利率 | 10.0% | 34.4% |
| 营收同比 | 12.9% | 4.8% |
| 净利润同比 | 4.0% | 2.9% |
| 每股收益（稀释后） | — | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PJTRPRX
| Q4 25 | $531.4M | $622.0M | ||
| Q3 25 | $442.3M | $609.3M | ||
| Q2 25 | $401.1M | $578.7M | ||
| Q1 25 | $321.9M | $568.2M | ||
| Q4 24 | $470.5M | $593.6M | ||
| Q3 24 | $320.3M | $564.7M | ||
| Q2 24 | $358.1M | $537.3M | ||
| Q1 24 | $327.1M | $568.0M |
净利润PJTRPRX
| Q4 25 | $53.4M | $214.2M | ||
| Q3 25 | $39.8M | $288.2M | ||
| Q2 25 | $32.9M | $30.2M | ||
| Q1 25 | $54.0M | $238.3M | ||
| Q4 24 | $51.3M | $208.2M | ||
| Q3 24 | $22.1M | $544.0M | ||
| Q2 24 | $28.3M | $102.0M | ||
| Q1 24 | $32.6M | $4.8M |
营业利润率PJTRPRX
| Q4 25 | 23.1% | 62.4% | ||
| Q3 25 | 20.6% | 70.1% | ||
| Q2 25 | 19.1% | 36.3% | ||
| Q1 25 | 16.3% | 94.0% | ||
| Q4 24 | 21.9% | 60.9% | ||
| Q3 24 | 15.4% | — | ||
| Q2 24 | 18.0% | 50.2% | ||
| Q1 24 | 16.5% | -13.0% |
净利率PJTRPRX
| Q4 25 | 10.0% | 34.4% | ||
| Q3 25 | 9.0% | 47.3% | ||
| Q2 25 | 8.2% | 5.2% | ||
| Q1 25 | 16.8% | 41.9% | ||
| Q4 24 | 10.9% | 35.1% | ||
| Q3 24 | 6.9% | 96.3% | ||
| Q2 24 | 7.9% | 19.0% | ||
| Q1 24 | 10.0% | 0.8% |
每股收益（稀释后）PJTRPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | — | $0.67 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | — | $1.21 | ||
| Q2 24 | — | $0.23 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $538.9M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $308.2M | $9.7B |
| 总资产 | $1.8B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资PJTRPRX
| Q4 25 | $538.9M | $618.7M | ||
| Q3 25 | $400.5M | $938.9M | ||
| Q2 25 | $214.6M | $631.9M | ||
| Q1 25 | $194.3M | $1.1B | ||
| Q4 24 | $483.9M | $929.0M | ||
| Q3 24 | $148.8M | $950.1M | ||
| Q2 24 | $164.2M | $1.8B | ||
| Q1 24 | $215.5M | $843.0M |
总债务PJTRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益PJTRPRX
| Q4 25 | $308.2M | $9.7B | ||
| Q3 25 | $228.6M | $9.6B | ||
| Q2 25 | $167.4M | $9.5B | ||
| Q1 25 | $148.8M | $9.8B | ||
| Q4 24 | $187.0M | $10.3B | ||
| Q3 24 | $159.1M | $10.3B | ||
| Q2 24 | $133.8M | $9.8B | ||
| Q1 24 | $174.6M | $9.9B |
总资产PJTRPRX
| Q4 25 | $1.8B | $19.6B | ||
| Q3 25 | $1.7B | $19.3B | ||
| Q2 25 | $1.5B | $18.3B | ||
| Q1 25 | $1.4B | $17.6B | ||
| Q4 24 | $1.6B | $18.2B | ||
| Q3 24 | $1.6B | $18.0B | ||
| Q2 24 | $1.4B | $17.7B | ||
| Q1 24 | $1.3B | $16.1B |
负债/权益比PJTRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $155.7M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $138.6M | — |
| 自由现金流率自由现金流/营收 | 26.1% | — |
| 资本支出强度资本支出/营收 | 3.2% | — |
| 现金转化率经营现金流/净利润 | 2.92× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $480.4M | — |
8季度趋势，按日历期对齐
经营现金流PJTRPRX
| Q4 25 | $155.7M | $827.1M | ||
| Q3 25 | $256.1M | $702.6M | ||
| Q2 25 | $190.4M | $364.0M | ||
| Q1 25 | $-75.9M | $596.1M | ||
| Q4 24 | $195.7M | $742.5M | ||
| Q3 24 | $180.5M | $703.6M | ||
| Q2 24 | $193.6M | $658.2M | ||
| Q1 24 | $-38.8M | $664.6M |
自由现金流PJTRPRX
| Q4 25 | $138.6M | — | ||
| Q3 25 | $240.9M | — | ||
| Q2 25 | $178.9M | — | ||
| Q1 25 | $-77.9M | — | ||
| Q4 24 | $195.3M | — | ||
| Q3 24 | $178.5M | — | ||
| Q2 24 | $193.0M | — | ||
| Q1 24 | $-39.2M | — |
自由现金流率PJTRPRX
| Q4 25 | 26.1% | — | ||
| Q3 25 | 54.5% | — | ||
| Q2 25 | 44.6% | — | ||
| Q1 25 | -24.2% | — | ||
| Q4 24 | 41.5% | — | ||
| Q3 24 | 55.7% | — | ||
| Q2 24 | 53.9% | — | ||
| Q1 24 | -12.0% | — |
资本支出强度PJTRPRX
| Q4 25 | 3.2% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率PJTRPRX
| Q4 25 | 2.92× | 3.86× | ||
| Q3 25 | 6.43× | 2.44× | ||
| Q2 25 | 5.79× | 12.06× | ||
| Q1 25 | -1.41× | 2.50× | ||
| Q4 24 | 3.81× | 3.57× | ||
| Q3 24 | 8.15× | 1.29× | ||
| Q2 24 | 6.84× | 6.45× | ||
| Q1 24 | -1.19× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PJT
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
